--Alphabet Q1 Compensation Expenses Including Employee Severence Decline $1.3 Billion From Year Ago-February 2024-www.financetom.com

--Alphabet Q1 Compensation Expenses Including Employee Severence Decline $1.3 Billion From Year Ago

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Alphabet Q1 Compensation Expenses Including Employee Severence Decline $1.3 Billion From Year Ago

Apr 25, 2024 1:45 PM

04:25 PM EDT, 04/25/2024 (MT Newswires) --

Price: 177.86, Change: +19.91, Percent Change: +12.61

Previous page： Medirom Unit Secures Series A Investment From NFES Technologies; Shares Soar Pre-Bell Next page： BRIEF-Shift4 To Acquire Givex Corp.

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Medirom Unit Secures Series A Investment From NFES Technologies; Shares Soar Pre-Bell

Aug 26, 2024

08:35 AM EDT, 08/26/2024 (MT Newswires) -- Medirom Healthcare Technologies ( MRM ) said Monday that NFES Technologies agreed to be the lead investor in Medirom Mother Labs' series A financing round. NFES Technologies' participation in the financing round, which values Mother Labs at 9 billion yen ($62.5 million) on a pre-money basis, is expected to attract additional investors, Medirom...

BRIEF-Shift4 To Acquire Givex Corp.

Aug 26, 2024

Aug 26 (Reuters) - Shift4 Payments Inc ( FOUR ): * SHIFT4 TO ACQUIRE GIVEX CORP., GLOBAL PROVIDER OF GIFT CARD, LOYALTY & POINT-OF-SALE SOLUTIONS Source text for Eikon: Further company coverage: ...

McKesson to buy controlling stake in Florida Cancer Specialists' unit for about $2.5 bln

Aug 26, 2024

Aug 26 (Reuters) - Drug distributor McKesson said on Monday it would buy a controlling stake in community cancer center Florida Cancer Specialists & Research Institute's business and administrative services unit, Core Ventures, for $2.49 billion in cash. McKesson would acquire about a 70% stake in the unit, which would be part of its U.S. pharmaceutical segment. Upon the close...

MIRA Pharmaceuticals Shares Surge Pre-Bell on 'Significant' Ketamir-2 Study Data

Aug 26, 2024

08:36 AM EDT, 08/26/2024 (MT Newswires) -- MIRA Pharmaceuticals ( MIRA ) shares surged nearly 46% in Monday's premarket activity after reporting that a pre-clinical study in rats showed that its ketamine analog, Ketamir-2, resulted in a 100% normalization of pain thresholds at the highest dose. This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under...